Adding Medical Cannabis to Opioids Reduced Pain in Hospice Patients With Few Side Effects

The combination of medical cannabis (CBD-dominant formulation) and scheduled opioids showed a statistically significant longitudinal reduction in pain intensity (p = .0029). A non-significant trend toward lower opioid doses was observed. Well-being, appetite, nausea, and respiratory function showed non-significant changes. Only 3 of 66 patients (4.5%) had minor, reversible adverse events. No serious or life-threatening events occurred.

Single-arm study of 66 hospice inpatients using scheduled oral, parenteral, or transdermal opioids. Patients received standardized oral medical cannabis: 40 mg CBD/1.5 mg THC or 80 mg CBD/3 mg THC. Outcomes assessed over 996 treatment days using the Mann-Whitney test and longitudinal mixed effects regression.

Pain management in end-of-life care often requires escalating opioid doses with increasing side effects. Adding a CBD-dominant cannabis formulation achieved significant additional pain relief without serious adverse events, potentially allowing patients to maintain comfort with lower opioid-related toxicity.

Hospice care is one of the most ethically straightforward settings for cannabis research -- the priority is comfort, not long-term safety concerns. These preliminary results support the rationale for cannabis as a complement to opioids in end-of-life care, where quality of life during remaining time is the primary goal.

Single-arm design without placebo control means the placebo effect and natural disease progression cannot be separated from treatment effects. The predominantly White, cancer-diagnosis sample limits generalizability. The CBD-dominant formulation may not represent all cannabis products used in palliative settings.